IDH Mutations in AML: Updates in Diagnostic Testing and Clinical Data Leading to Precision Treatment
December 11, 2024 8:00PM - 9:30PM EST
Event Details
Selecting treatment for patients with IDH1- or IDH2-mutated AML is challenging. Several regimens are available, including novel therapies that specifically target IDH1 or IDH2, but questions remain about optimal sequencing of new and existing therapies for these patients. Hear the expert faculty weigh in on crucial issues of diagnosis and treatment within this patient population.